STRATA Shares Plummet 21% as Johns Hopkins Adds Excimer Laser

XTRAC 308 nm laser to expand advanced care for chronic skin conditions at Johns Hopkins Dermatology

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

STRATA Skin Sciences, Inc. (SSKN) saw its stock price drop more than 21% despite the company's announcement that Johns Hopkins Dermatology has added the XTRAC 308 nm excimer laser to its clinical offerings. The addition strengthens Johns Hopkins' capabilities in treating psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic diseases using targeted, FDA-cleared phototherapy.

Why it matters

The collaboration between STRATA and Johns Hopkins highlights the growing importance of precision treatment strategies and expanding access to excimer laser therapy for managing challenging inflammatory skin conditions. As a leading academic medical center, Johns Hopkins' adoption of the XTRAC laser reinforces its commitment to evidence-based dermatologic innovation.

The details

The XTRAC excimer laser delivers targeted 308 nm phototherapy, allowing clinicians to treat inflammatory skin conditions with precision while minimizing exposure to surrounding healthy skin. In addition to patient care, the system will support ongoing clinical research and academic initiatives within the department. Johns Hopkins joins a growing list of leading academic institutions that have integrated XTRAC into their dermatology programs.

  • STRATA Skin Sciences, Inc. (SSKN) announced the collaboration with Johns Hopkins Dermatology on February 18, 2026.

The players

STRATA Skin Sciences, Inc.

A medical technology company that develops, commercializes, and markets products for the treatment of dermatologic conditions.

Johns Hopkins Dermatology

The dermatology department at Johns Hopkins University, a leading academic medical center known for its excellence in patient care, research, and education.

Dr. Dolev Rafaeli

The CEO of STRATA Skin Sciences, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“The collaboration highlights the critical role academic medical centers play in advancing precision treatment strategies and expanding access to excimer laser therapy.”

— Dr. Dolev Rafaeli, CEO, STRATA Skin Sciences, Inc.

What’s next

The addition of the XTRAC excimer laser to Johns Hopkins Dermatology's clinical offerings is expected to strengthen the department's capabilities in treating chronic inflammatory and autoimmune skin conditions, while also supporting ongoing research and academic initiatives.

The takeaway

The partnership between STRATA and Johns Hopkins underscores the growing recognition of the value of precision treatment strategies, like excimer laser therapy, in managing complex dermatologic diseases. As a leading academic medical center, Johns Hopkins' adoption of the XTRAC laser reinforces its commitment to evidence-based innovation and expanding access to advanced care for patients.